Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.66 USD
-0.03 (-1.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.65 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 170 | 138 | 87 | 152 | 272 |
Receivables | 1 | 0 | 0 | 0 | 57 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 4 |
Other Current Assets | 5 | 2 | 2 | 5 | 5 |
Total Current Assets | 177 | 141 | 89 | 158 | 338 |
Net Property & Equipment | 2 | 2 | 1 | 0 | 14 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 45 | 45 | 45 | 45 | 64 |
Deposits & Other Assets | 1 | 0 | 2 | 1 | 2 |
Total Assets | 229 | 194 | 137 | 204 | 418 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 10 | 9 | 5 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 12 | 11 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 13 | 13 | 30 | 42 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 32 | 23 | 22 | 47 | 65 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 100 | 49 | 0 | 0 | 234 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 136 | 77 | 23 | 47 | 301 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,863 | 1,709 | 1,609 | 1,561 | 1,462 |
Retained Earnings | -1,767 | -1,590 | -1,488 | -1,400 | -1,341 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 3 | 2 | 8 | 5 | 4 |
Total Shareholder's Equity | 93 | 117 | 114 | 156 | 117 |
Total Liabilities & Shareholder's Equity | 229 | 194 | 137 | 204 | 418 |
Total Common Equity | 93 | 117 | 114 | 156 | 117 |
Shares Outstanding | 245.70 | 188.70 | 148.90 | 121.10 | 106.20 |
Book Value Per Share | 0.38 | 0.62 | 0.76 | 1.29 | 1.10 |
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 310 | 356 | 170 | 218 | 257 |
Receivables | 3 | 2 | 1 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 0 | 0 | 0 |
Other Current Assets | 8 | 7 | 5 | 4 | 6 |
Total Current Assets | 321 | 365 | 177 | 223 | 264 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 45 | 45 | 45 | 45 | 45 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 373 | 417 | 229 | 276 | 317 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 8 | 14 | 12 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 15 | 17 | 20 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 28 | 23 | 32 | 32 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 100 | 100 | 100 | 99 | 99 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 133 | 128 | 136 | 137 | 130 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,113 | 2,109 | 1,863 | 1,859 | 1,856 |
Retained Earnings | -1,869 | -1,815 | -1,767 | -1,717 | -1,667 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 5 | 5 | 3 | 3 | 3 |
Total Shareholder's Equity | 240 | 289 | 93 | 140 | 186 |
Total Liabilities & Shareholder's Equity | 373 | 417 | 229 | 276 | 317 |
Total Common Equity | 240 | 289 | 93 | 140 | 186 |
Shares Outstanding | 246.20 | 246.20 | 245.70 | 244.90 | 244.90 |
Book Value Per Share | 0.97 | 1.17 | 0.38 | 0.57 | 0.76 |